Why the study?
Does metformin alter metabolic profiles and do these metabolites predict LVEF and infarct size in patients with STEMI?
Does metformin alter metabolic profiles and do these metabolites predict LVEF and infarct size in patients with STEMI?
HDL triglyceride concentrations predict post-MI LVEF and infarct size, and metformin alters specific metabolic pathways including alanine and HDL phospholipid content.
No takes yet. Share an insight, caveat, or question.
Early HDL triglycerides may aid post-MI risk stratification; RCT extends metformin's effects on HDL composition in STEMI.
Eppinga et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: